Merz to Create Three Independent, Customer-Focused Healthcare Businesses to Drive Growth
Merz, a global, diversified healthcare company, has announced plans for a new business structure that will enable the company to better address customer and patient needs, shorten innovation cycles and capitalize on new market opportunities.
The new organizational structure will consist of three independently operating businesses: Merz Aesthetics, Merz Therapeutics and Merz Consumer Care. This new structure will allow for more specialized customer focus and will increase operational agility and speed to market. The creation of three separate businesses is expected to continue fuelling the strong growth seen across all business areas in fiscal year 2018/19.
"We have achieved strong results in all of our core businesses in the most-recently completed fiscal year 2018/19. This is now the right time for us to structure our operations into three independent businesses fully focused on their specific customers and market needs,” says Philip Burchard, Chief Executive Officer of the Merz Group. "From this position of strength, each individual business will have more independence, accountability and empowerment to drive long-term sustainable growth.”
New global leadership appointments within Merz
Merz Aesthetics will operate exclusively in the field of medical aesthetics and focus on serving customer needs in a rapidly changing and dynamic environment. This business aims at a strong presence and performance in all key global markets and will continue to offer a full portfolio across injectables (dermal fillers and botulinum toxin), energy-based devices and professional skincare. Bob Rhatigan has been appointed CEO of Merz Aesthetics and will continue to be based in Raleigh, North Carolina, USA.
Merz Therapeutics will generate a long-term, sustainable pipeline centered on the movement disorders space and our core neurotoxin product, Xeomin® (incobotulinumtoxinA). Business priorities will be to continue to deliver on patient and healthcare provider needs including launching new indications and adding new products to create a portfolio. Stefan Brinkmann has been appointed CEO of Merz Therapeutics and will continue to be based in Frankfurt, Germany.
Merz Consumer Care will focus on new growth opportunities in order to expand its success in new areas and strengthen its agile, customer-oriented culture as a fast-moving consumer goods (FMCG) business; Consumer Care will continue to pursue leading market positions in all its product categories with its flagship brands tetesept and Merz Spezial. Frank Baldauf remains in his role as CEO of Merz Consumer Care and will continue to be based in Frankfurt, Germany.
These new leadership roles go into effect as of January 1, 2020. Merz expects to be fully operating in the new business structure at the beginning of fiscal year 2020/21.
While each business will be led by fully empowered leadership teams, all three businesses will continue to operate as part of the Merz Group, under the governance of the Merz Shareholder Council and Supervisory Board and under the ownership of the Merz family shareholders. Philip Burchard will continue acting as Merz Group CEO, while simultaneously holding the role of Chairman of the Shareholder Council, with effect as of November 1, 2019.
Financial results for fiscal year 2018/19
Merz reported total revenue of EUR 1,094 million for fiscal year 2018/19 (previous year: EUR 1,024 million). Overall, Merz revenue grew by 6.8 percent vs. prior year. Core business areas (Aesthetics, Therapeutics, Consumer Care) grew 13.5 percent versus prior year and accounted for approximately 90 percent of the total revenue; income from memantine licensing and contract manufacturing activities made up the remainder. All three businesses gained market share as they grew faster than their respective markets. For fiscal year 2018/19, earnings before interest and taxes (EBIT) increased to EUR 137.5 million (previous year: EUR 93 million).
"Our strong financial performance in fiscal year 2018/19 demonstrates that we are on the right track with our global strategy as a focused yet well-diversified healthcare company," says Philip Burchard, Chief Executive Officer of the Merz Group. “Merz has continued to develop its leadership position and expand its market share in the areas of medical aesthetics, neurotoxin therapy and consumer care products. By strengthening and developing each of these focus areas as independent businesses, we are confident that we will continue to build on this success in the years to come.”
Merz is a global, diversified healthcare company based in Frankfurt, Germany. Privately-held for more than 111 years, the company operates in the areas of aesthetics, therapeutics and consumer care and is distinguished by its commitment to innovation, long-term perspective and focus on profitable growth. In fiscal year 2018/19, Merz generated revenue of EUR 1,094 million; the company has a total workforce of 3,151 employees worldwide and a direct presence in 28 countries. More information is available at www.merz.com.
Copyright © 2019 Merz Pharma GmbH & Co. KGaA. All rights reserved. MERZ, MERZ AESTHETICS and the MERZ logo are registered trademarks of Merz Pharma GmbH & Co. KGaA.
Merz Pharma GmbH & Co. KGaA
Phone: +49 69 1503 6246
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Seoul Semiconductor’s SunLike Natural Spectrum LEDs Adopted by Fiberli Grow Light for Horticulture Projects in Turkey6.7.2020 12:00:00 EEST | Press release
Seoul Semiconductor Co., Ltd. (KOSDAQ 046890), a leading global innovator of LED products and technology, announced that its SunLike Series natural spectrum LEDs have been adopted for horticulture LED lighting by the lighting solution company Fiberli, located in Turkey, one of the largest agricultural exporters in the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200706005073/en/ Seoul Semiconductor’s SunLike Natural Spectrum LEDs Adopted by Fiberli Grow Light for Horticulture Projects in Turkey (Photo: Business Wire) While it is well known that natural sunlight is one of the key factors in growth cycle of a plant, most growers cultivating a variety of crops under sunlight have experienced difficulties in regulating their growth cycles due to adverse seasonal conditions. Replacing sunlight with LED lighting that closely matches natural sunlight enables growers to control the growth cycles and development of all types
Sabio Group Acquires Coverage Group in France6.7.2020 11:00:00 EEST | Press release
Sabio Group has announced the acquisition of Coverage Group, one of France’s leading independent providers of customer experience and communications technology solutions. The acquisition supports Sabio’s goal of becoming the leading player across the European CX market and will add significant scale to the company’s French operations. Formed in 2007, Paris-based Coverage Group is an established Genesys Gold, Avaya Edge, Oracle Gold and Broadsoft technology partner. The company has a proven track record in helping organisations across France to place cloud-based customer experience solutions at the heart of their digital strategy, with customers including ENGIE, BEA, EBP, Emil Frey, Homeserve, NutriXo, Optimind, Pierre Fabre, Pierre & Vacances, Sitel and Teleperformance. “The acquisition is a massively important strategic addition for Sabio Group and our customers in a number of ways – it means we have now built a substantial presence and customer base in France, it further strengthens
BearingPoint helps government and public sector organizations deliver critical health and public services during the Covid-19 pandemic6.7.2020 10:00:00 EEST | Press release
Management and technology consultancy BearingPoint announced today that it is helping its government and public sector clients across Europe to deliver critical health and public services during the Covid-19 pandemic through new delivery models, new ways of working, digitalization, and automation. “BearingPoint’s organization as a single, European-based business has meant we have been able to draw on capabilities, leading practices and learnings from across our government and public sector clients and teams in many different countries. Working remotely and in partnership with our clients, we have quickly mobilized resources to design and deliver solutions to support both the public services needed during Covid-19 and the new ways of working for public servants,” said Andrew Montgomery, Partner and Global Leader Government and Public Sector at BearingPoint. New delivery models and services People’s health and well-being during the Covid-19 crisis have required public services to rapidly
DNA Selects VisualOn’s OnStream® Android TV to Deliver the Highest Quality of Service for Their Over the Top (OTT) Deployment on the Android TV Platform6.7.2020 09:00:00 EEST | Press release
VisualOn, Inc., a streaming software provider that enables scalable, cross-platform media playback for leading video services, today announced that the company is now providing DNA's end users the ability to stream the highest quality video using the Android TV. DNA is Finland's largest cable operator. Launched in February this year, the new DNA TV has revamped DNA’s TV offering for IP-based delivery, introducing multiple features including unlimited NPVR recordings, a new user interface and improved video stream quality. Through its innovative program-centric approach, subscribers can view and record unlimited TV programs with unprecedented ease of use and watch live and VOD content whenever they want, anywhere in the EU via the DNA TV app. Furthermore, the service delivers compelling content recommendations based on users’ individual viewing preferences. VisualOn, powered by AWS, has closely supported DNA to build and deploy this platform. “Service reliability and a seamless user exp
Excelya Welcomes Three European Contract Research Organizations to Become One Stop Provider Throughout Europe6.7.2020 09:00:00 EEST | Press release
Today, Excelya, a leading contract research organization (CRO) specializing in clinical research, announced that three European CROs joined Excelya Group: Zeincro based in Central-Eastern & Southern Europe, The Clinical Company based in the Netherlands and Belgium and Koehler eClinical based in Germany. Together, they will be known as Excelya Group. This alliance will allow Excelya to offer a one stop provider service model throughout Europe for its clients, whether they need full service, functional service providing or consulting services. Zeincro is a leading contract research organization primarily operating in Central-Eastern & Southern Europe with particular expertise in clinical operations, safety and medical affairs. The Clinical Company is present in the Belgian and Dutch markets specializing in clinical operations. Koehler eClinical is a German specialty CRO with a focus on biostatistics and data solutions. Thanks to the unification with these three companies, Excelya Group i
EMA Validates and Grants Accelerated Assessment for Trastuzumab Deruxtecan for the Treatment of HER2 Positive Metastatic Breast Cancer6.7.2020 09:00:00 EEST | Press release
Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced that the European Medicines Agency (EMA) has validated the Marketing Authorization Application (MAA) for trastuzumab deruxtecan, a HER2 directed antibody drug conjugate (ADC), for the treatment of adults with unresectable or metastatic HER2 positive breast cancer who have received two or more prior anti-HER2 based regimens. Trastuzumab deruxtecan was granted accelerated assessment by the EMA’s Committee for Medicinal Products for Human Use (CHMP). Validation confirms that the application is complete and commences the scientific review process by the EMA’s CHMP. Accelerated assessment is granted by the CHMP to products expected to be of major interest for public health and therapeutic innovation and can significantly reduce the review timelines. “The accelerated assessment highlights the significant unmet need for patients with HER2 positive metastatic breast cancer that trastuzumab deruxtecan aims at addressing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom